Intellia Posts $127.5M Q3 Loss as Cash Burn Accelerates
NTLA sits 55% above its 52-week low of $7.95.
Summary
Intellia reported a third-quarter net loss of $127.5 million, up from the $106.6 million loss it posted in Q2 2026, with a loss per share of 91c and revenue of $7.16 million. Research and development expenses came in at $83.3 million. The widening deficit matters for a clinical-stage gene-editing company whose story rests on funding the lonvo-z launch without heavy dilution. It follows the $400 million OrbiMed term loan closed in September, of which only $75 million was drawn upfront, and the FDA's Priority Review acceptance of the lonvo-z BLA. Intellia expects the lonvo-z launch in Q1 2027, and the PDUFA date for lonvo-z is March 10, 2027.
At the time of this announcement, NTLA was trading at $12.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $7.95 to $18.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.